The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InBarclays analysts have issued a bullish outlook for Ionis Pharmaceuticals (IONS), setting a new price target of $106 per share. This target implies a potential upside of approximately 45% from the stock's current trading level of $72.70. While the stock has experienced a 6.12% decline since the beginning of 2026, its long-term performance remains robust with a 137.52% gain over the past year. Currently, the shares are trading about 7.20% below their recent one-month high, presenting what analysts view as a significant valuation gap. The positive projection reflects institutional confidence in the company's growth prospects within the biotechnology sector. Investors are closely monitoring the NASDAQ-listed firm as it navigates recent market volatility and analyst re-ratings.